Guided Therapeutics Inc. (OTCMKTS:GTHP) Stock Short Interest Falls 45.4%

by · The Markets Daily

Guided Therapeutics Inc. (OTCMKTS:GTHP – Get Free Report) was the target of a large drop in short interest in September. As of September 30th, there was short interest totaling 3,727 shares, a drop of 45.4% from the September 15th total of 6,822 shares. Based on an average daily trading volume, of 127,857 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company’s stock are sold short.

Guided Therapeutics Price Performance

Shares of Guided Therapeutics stock remained flat at $0.19 on Friday. 110 shares of the stock were exchanged, compared to its average volume of 20,623. The firm’s 50-day moving average price is $0.23 and its 200 day moving average price is $0.24. Guided Therapeutics has a 52-week low of $0.15 and a 52-week high of $0.54. The stock has a market cap of $18.66 million, a PE ratio of -4.75 and a beta of 0.70.

Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.01) EPS for the quarter.

Guided Therapeutics Company Profile

(Get Free Report)

Guided Therapeutics, Inc is a medical technology company focused on developing diagnostic products for women’s health. The company’s primary focus has been the detection of cervical disease and cancer using minimally invasive or non-invasive technologies.

Its lead product, LuViva Advanced Cervical Scan, is designed to evaluate cervical tissue using optical spectroscopy. The system analyzes changes in tissue characteristics that may be associated with precancerous or cancerous conditions and is intended to help clinicians identify patients who may require additional evaluation, including biopsy.

Guided Therapeutics has pursued regulatory and commercial opportunities for its cervical disease detection technology in the United States and international markets.

Recommended Stories